Figure 9

Treatment with PLGA-PEG^PS341 attenuates NFκB mediated inflammatory response. The Cftr^-/- mice (n = 3, each group) were treated with Pa-LPS and/or PLGA-PEG^PS341. Control, untreated group, was treated with 10 μl saline. The lung tissue was isolated on day-3 and total protein extract was used for immunoblotting. The treatment with the PLGA-PEG^PS341 significantly decreases Pa-LPS induced NFκB levels confirming that PLGA-PEG mediated PS-341 delivery controls NFκB mediated inflammatory response in murine model. β-actin shows the equal loading. The data verifies the efficacy of PLGA-PEG mediated PS-341 drug delivery in controlling NFκB mediated lung disease.